Psilocybin for Alcohol Use Disorder: The Johns Hopkins Breakthrough Study

What Is Alcohol Use Disorder, and Why Do Current Treatments Fall Short?

Alcohol use disorder, or AUD, is a medical condition marked by an impaired ability to stop or control drinking despite negative consequences. It sits on a spectrum from mild to severe, and it is common. Roughly one in seven American adults meets criteria for it in a given year, and close to a third will meet criteria at some point in their lifetime.

Despite how widespread it is, treatment reaches very few people. Fewer than five percent of adults diagnosed with AUD receive any formal treatment, and fewer than one percent receive medication for it. Three drugs carry FDA approval for AUD: naltrexone, acamprosate, and disulfiram. They help some people, but their effects are generally modest, and many who try them relapse. That gap between the scale of the problem and the strength of available tools is exactly what has drawn researchers back to psychedelics.

Why Are Researchers Studying Psilocybin for Alcohol Use Disorder?

The interest is not new. In the 1950s and 1960s, researchers ran dozens of studies using LSD to treat alcoholism, some with encouraging results, before that entire line of work was shut down for decades. When the modern psychedelic research era began, addiction was one of the first areas scientists returned to, and psilocybin became a leading candidate.

Part of the rationale is mechanistic. Psilocybin appears to produce a temporary window of increased neuroplasticity, a period in which the brain becomes more flexible and better able to form new connections. For someone locked into the deeply grooved patterns of compulsive drinking, that window may create an opening for change that ordinary talk therapy alone struggles to reach. Many participants also describe a single experience as producing a shift in how they see themselves and their relationship to alcohol, rather than a gradual chipping away at a habit.

Here is what we can say with confidence: this is not about intoxication replacing intoxication. In the clinical model, psilocybin is used a small number of times inside a structured course of psychotherapy, not taken repeatedly. The therapy surrounding the sessions is considered essential to the outcome, not an add-on.

What Did the Landmark Psilocybin Trial Actually Show?

The pivotal study was published in JAMA Psychiatry in 2022, led by Michael Bogenschutz and colleagues. It was a double-blind randomized controlled trial, the most rigorous design available, and it enrolled 93 adults with alcohol use disorder who received at least one dose of study medication.

Participants were assigned to one of two groups. One group received psilocybin. The other received diphenhydramine, an antihistamine used as an active placebo because it produces noticeable physical effects without the psychedelic experience, which helps keep participants and researchers genuinely blinded. Everyone in both groups received the same 12 weeks of structured psychotherapy. Each person had two full day-long medication sessions, at roughly the four-week and eight-week marks.

The dosing followed a weight-based protocol. The first session used 25mg of psilocybin per 70kg of body weight, roughly equivalent to 3 to 4g of dried Psilocybe cubensis for an average-sized adult. The second session went higher, up to 30 to 40mg per 70kg, in the range of 4 to 5g of dried mushrooms, though it is worth noting that psilocybin content varies considerably by strain and specimen, so weight alone is an imperfect guide.

The primary result was clear. Over the 32-week period after the first dose, the psilocybin group spent 9.7 percent of days heavy drinking, compared with 23.6 percent in the placebo group. That is a mean difference of about 14 percentage points, a large and statistically significant gap. Daily alcohol consumption was lower in the psilocybin group as well. Importantly for a compound this potent, there were no serious adverse events among participants who received psilocybin.

How Strong Is This Evidence, Really?

This is where things get more nuanced, and honesty matters more than enthusiasm. The 2022 trial is genuinely significant. It was the first modern randomized controlled trial of psilocybin for AUD, and its design was strong. But it is one trial, at two research centers, with fewer than 100 participants. In evidence terms, this is a promising Tier 2 signal, not a settled Tier 1 conclusion.

Several honest caveats apply. The blinding challenge that affects all psychedelic research is present here too. Many people can tell whether they received a genuine psychedelic or a placebo, which can influence expectations and outcomes. The participant group was also predominantly non-Hispanic White, which limits how confidently the findings extend to everyone. And a single positive trial, however well run, is a starting point rather than a finish line.

The picture since 2022 has grown more textured. Newer trials in Europe have produced more mixed results, a reminder that early enthusiasm often meets complexity as research scales up. That does not undo the 2022 findings. It reinforces why the responsible framing is cautious optimism, and why anyone considering this path should understand they are looking at an emerging treatment, not an established one.

It also helps to see the 2022 trial in its lineage. The same research group ran a small open-label proof-of-concept study back in 2015, which suggested psilocybin might reduce drinking but lacked a control group, so it could not rule out expectation and placebo effects. The 2022 trial was designed specifically to address that weakness, which is why its randomized, placebo-controlled structure carries more weight. Larger multi-site trials are now underway, and their results over the next few years will do far more to settle the question than any single study can on its own.

Is Psilocybin Treatment for Alcohol Use Disorder Legally Available?

For most people in the United States, the answer is that legal access is narrow. Psilocybin remains a Schedule I substance under federal law. The two exceptions are Oregon and Colorado, which have established regulated frameworks for supervised psilocybin services, though these operate as wellness and supported-use programs rather than as medical treatment for a specific diagnosis like AUD.

Ongoing clinical trials are another route, and enrollment is sometimes open to people who meet study criteria. Outside of these settings, unsupervised or underground use carries real risks, especially for someone with a history of heavy alcohol use, which can complicate both the physical and psychological picture. For a fuller view of where things stand nationally, our state-level breakdowns of psychedelic therapy access lay out the current legal landscape.

What Would Responsible Treatment Look Like?

Whatever the setting, the research points to a consistent lesson. The psilocybin sessions were never the whole intervention. They sat inside a careful arc of preparation, professional support during the experience, and integration afterward, the work of making sense of what surfaced and translating it into lasting change.

This matters because alcohol use disorder is rarely just about alcohol. It often intertwines with trauma, depression, anxiety, and long-standing patterns of coping. A single powerful experience can open a door, but walking through it takes structure and skilled human support. That is why screening also matters so much here. Certain medical and psychiatric histories call for real caution before any psychedelic work, and a thorough evaluation is not a formality.

For readers interested in how these medicines are thought to work at a deeper level, our complete guide to psilocybin and its therapeutic use covers the science, the forms it takes, and what the wider evidence base shows. The throughline in all of it is the same: safety and support are not optional extras. They are the foundation.